Richard Lafayette, MD, FACP, Stanford University Medical Center, explains the significance of this second approval in a month ...

Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug. The US regulator ...

The global gene therapy market is projected to grow at a significant CAGR of 20% from 2024 to 2029. This growth is driven by ...

Amgen's strategic growth through M&A and R&D investments has led to a diversified portfolio. Find out why I give AMGN stock a ...

Novartis' head of medical affairs Ameet Nathwani talks about the remarkable story of Entresto's accelerated development, and plans for a novel pricing. As the ink dries on the US approval of ...

Analysts have had to throw out their assumptions for the biopharma industry’s recovery heading into the first quarter ...

The psoriasis pipeline possesses some drugs in mid- and late-stage development to be approved in the near future. The emerging landscape holds a dive ...

A three-judge panel wrestled Thursday with Novartis AG’s challenge against the FDA over its approval of a generic version of ...

Spruce Biosciences has put out new shoots, snapping up rights to a former BioMarin rare disease candidate and outlining plans ...

J.P. Morgan analyst Richard Vosser reiterated a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF95.00.

Detailed price information for Oncolytics Biotech Inc (ONCY-Q) from The Globe and Mail including charting and trades.